[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638090":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, Berkeley","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nasal Spray Treatment Group","EXPERIMENTAL","Participants to be dispensed varenicline nasal spray 0.03mg solution and self-administer one spray in each nostril twice daily, approximately 12 hours apart, for 3 months.",[13],"Drug: Varenicline 0.03Mg\u002FSpray Nasal Soln",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Varenicline 0.03Mg\u002FSpray Nasal Soln","After meeting eligibility criteria and signing informed consent, participants will be dispensed a 3-month supply of varenicline 0.03mg\u002Fspray nasal solution. Participants will take the nasal spray home and spray once in each nostril twice daily for 3 months",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Meng C. Lin, OD, PhD","CONTACT","510-643-9252","mlin@berkeley.edu",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Laimeng Lee, OD, MS","laimenglee@berkeley.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"U.C. Berkeley Clinical Research Center","RECRUITING","Berkeley","California","94720","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-122.27275,37.87159,{"lat":43,"lon":42},[46,47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"Viatris Inc.","INDUSTRY","100638090","phase-4-ocular-surface-health-and-tear-film-stability-with-a-nasal-spray-dry-eye-treatment-100638090",false,"NCT07606625","Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment","The Impact of Varenicline Nasal Spray 0.03mg Dry Eye Treatment on Ocular Surface Health, Tear Film Stability, and Ocular Discomfort","Inclusion Criteria:\n\n* Is 18 years of age and has full legal capacity to volunteer (no max age requirement)\n* Baseline Ocular Surface Disease Index (OSDI) \\>13\n* Has mild to moderate MGD\n* Has best corrected visual acuity of 20\u002F40 or better\n* Has had an oculo-visual examination in the last two years\n* Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and\u002For eyelid margin cleaning)\n* Is willing to discontinue other prescription medications for dry eye disease (DED) management\n* Is willing to stop any topical eye drops before all planned visits\n* Has read, understood, and completed the informed consent letter\n\nExclusion Criteria:\n\n* Is participating in any other type of clinical or research study\n* Is currently pregnant, nursing, lactating, or planning a pregnancy\n* Is currently having \\>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD)\n* Is currently using any topical ocular medications\n* Has chronic or currently active sinus related problems\n* Has blepharitis \\> grade 1\n* Has active ocular infections\n* Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study\n* Has received Rx DED treatment within one week of enrollment\n* Has received any thermal or light-based DED treatment within 30 days of enrollment\n* Has significant corneal epithelial defects\n* Has abnormal eyelid anatomy\n* Has corneal neuropathic pain\n* Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding\n* Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment\n* Has a known allergy to a product used in this study","ALL","18 Years",{"count":64,"type":65},65,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).",[71,72],"Dry Eye","Meibomian Gland Dysfunction",[74,75,76,77,78,79,80,81,82],"Dry eye disease","Meibomian gland dysfunction","Varenicline","Nasal spray dry eye treatment","Tear lipid layer","Tear thinning","Tear production","Tear film stability","Ocular discomfort","2026-05-22",{"date":85,"type":86},"2026-05-27","ACTUAL",{"date":88,"type":86},"2026-03-06",{"date":90,"type":65},"2026-12-31",{"name":5,"class":6},1]